Hahn T J, Birge S J, Scharp C R, Avioli L V
J Clin Invest. 1972 Apr;51(4):741-8. doi: 10.1172/JCI106868.
The metabolic fate of intravenously injected vitamin D(3)-1,2-(3)H (D(3)-(3)H) was studied in two normal individuals on chronic phenobarbital therapy. Silicic acid column chromatography of lipid-soluble plasma extracts obtained serially for 96 hr after D(3)-(3)H injection demonstrated a decreased plasma D(3)-(3)H half-life and increased conversion to more polar metabolites. The polar metabolites formed included several with chromatographic mobility similar to known biologically inactive vitamin D metabolites and one with chromatographic mobility identical to 25-hydroxycholecalciferol. Disappearance of this latter material was also accelerated. A child with rickets and a normal volunteer studied before and after a 2 wk course of phenobarbital therapy demonstrated similar alterations in D(3)-(3)H metabolism. When liver microsomes from 3-wk-old Sprague-Dawley rats treated with phenobarbital were incubated with D(3)-(3)H, polar metabolites were produced with chromatographic mobility similar to the plasma D(3)-(3)H metabolites from phenobarbital-treated humans. Similar incubations employing 25-hydroxy-cholecalciferol-26-27-(3)H as the substrate also demonstrated an increased conversion to polar metabolites. The data suggest that the reported increased incidence of osteomalacia observed in patients on chronic anticonvulsant therapy may be the result of an accelerated conversion of vitamin D and its active metabolite, 25-hydroxycholecalciferol, to polar metabolites by druginduced liver microsomal enzymes.
在两名接受慢性苯巴比妥治疗的正常个体中研究了静脉注射维生素D(3)-1,2-(3)H(D(3)-(3)H)的代谢命运。在注射D(3)-(3)H后连续96小时获得的脂溶性血浆提取物的硅酸柱色谱分析表明,血浆D(3)-(3)H半衰期缩短,且转化为极性更强的代谢产物的转化率增加。形成的极性代谢产物包括几种色谱迁移率与已知生物活性维生素D代谢产物相似的物质,以及一种色谱迁移率与25-羟基胆钙化醇相同的物质。后一种物质的消失也加快了。一名佝偻病患儿和一名正常志愿者在接受为期2周的苯巴比妥治疗前后进行研究,结果表明D(3)-(3)H代谢有类似变化。当用苯巴比妥处理的3周龄Sprague-Dawley大鼠的肝微粒体与D(3)-(3)H一起孵育时,产生的极性代谢产物的色谱迁移率与苯巴比妥处理的人类血浆D(3)-(3)H代谢产物相似。以25-羟基胆钙化醇-26-27-(3)H为底物进行的类似孵育也表明转化为极性代谢产物的转化率增加。数据表明,在接受慢性抗惊厥治疗的患者中观察到的骨软化症发病率增加,可能是药物诱导的肝微粒体酶加速将维生素D及其活性代谢产物(即25-羟基胆钙化醇)转化为极性代谢产物的结果。